Pentixapharm Publishes Half-Year Figures for 2025
Loss of the reporting period €8.4 million (attributed to research and development activities, personnel and other operating expenses)
Revenue of the reported period €38 thousands
Balance sheet total as of June 30, 2025: €51 million
Guidance for the fiscal year 2025 published on April 14, 2025 remains unchanged: expected loss approximately €23.5 million
Berlin and Würzburg, Germany, 06 August 2025
The Executive Board of Pentixapharm Holding AG announced the following today:
Based on the newly published interim financial statements, the Group closed the first half of the 2025 fiscal year with a loss of EUR 8.4 million.
Based on current planning, the Company continues to expect a net loss for the full 2025 fiscal year of approximately EUR 23.5 million, consistent with the forecast published in April 2025.
This forecast includes research and development expenses of approximately EUR 11 million and personnel and other operating expenses of approximately EUR 9.5 million. Potential income from out-licensing is not included in the forecast.
The full interim financial statements is available on the Pentixapharm Holding AG Investor Relations website: www.pentixapharm.com/investors/reports.
About Pentixapharm
Pentixapharm is a biopharmaceutical company based in Berlin and Würzburg, dedicated to the development of innovative, targeted radiopharmaceuticals. The company is developing, among other programs, CXCR4 ligand-based radiopharmaceuticals for diagnostic and therapeutic use in various types of blood cancers, solid tumors, and endocrine diseases such as primary aldosteronism.
The pipeline is further complemented by radiolabeled antibodies currently in the preclinical proof-of-concept stage. These antibodies differentiate target proteins on healthy and tumor tissue based on their O-glycosylation patterns. This innovative approach holds the potential for low off-target binding and an improved therapeutic window, offering clear advantages over conventional radiopharmaceuticals.
For more information, please contact:
Pentixapharm Holding AG
Henner Kollenberg
ir@pentixapharm.com
Tel. +49 30 94892600
www.pentixapharm.com